Carlsmed

Q2 FY2026 EarningsQ2 FY26 results beat consensus estimates across the top line and key margin metrics. Revenue reached $18.94M, surpassing expectations by 5.53%, while gross margin exceeded forecasts by 1.23pct to hit 76.8%. GAAP EPS of -$0.39 was ahead of the -$0.41 consensus, driven by scaling volume in the aprevo platform and lower per-unit production fees. Net loss of -$10.51M also outperformed the expected -$11.01M despite increased OpEx to support public company requirements.